Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Bisaga

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors|March 18, 2009
Betting on change: modeling transitional probabilities to guide therapy development for opioid dependenceKenneth M Carpenter, Huiping Jiang, Maria A Sullivan, et al.
Journal of Dental Education|February 6, 2020
Innovations in pre-doctoral dental education: Influencing attitudes and opinions about patients with substance use disorderFolarin Odusola, Jennifer L Smith, Adam Bisaga, et al.
Journal of Psychoactive Drugs|September 12, 2018
The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and AnxietyJermaine D Jones, Adam Bisaga, Verena E Metz, et al.
The American Journal on Addictions|August 16, 2011
A comparison of independent depression and substance-induced depression in cannabis-, cocaine-, and opioid-dependent treatment seekersElias Dakwar, Edward V Nunes, Adam Bisaga, et al.
Pharmacology, Biochemistry, and Behavior|October 12, 2017
Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potentialJermaine D Jones, Sandra D Comer, Verena E Metz, et al.
Addiction (Abingdon, England)|January 10, 2013
A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disordersFrances R Levin, John Mariani, Daniel J Brooks, et al.
Journal of Dual Diagnosis|May 12, 2009
Atomoxetine Treatment for Cocaine Abuse and Adult Attention-Deficit Hyperactivity Disorder (ADHD): A Preliminary Open TrialFrances R Levin, John J Mariani, Alex Secora, et al.
Drug and Alcohol Dependence|January 4, 2015
Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexoneMaria A Sullivan, Adam Bisaga, Andrew Glass, et al.
Drug and Alcohol Dependence|January 8, 2021
Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trialFrances R Levin, John J Mariani, Martina Pavlicova, et al.
Drug and Alcohol Dependence|July 1, 2011
A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependenceAdam Bisaga, Maria A Sullivan, Wendy Y Cheng, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors|March 18, 2009
Betting on change: modeling transitional probabilities to guide therapy development for opioid dependenceKenneth M Carpenter, Huiping Jiang, Maria A Sullivan, et al.
Journal of Dental Education|February 6, 2020
Innovations in pre-doctoral dental education: Influencing attitudes and opinions about patients with substance use disorderFolarin Odusola, Jennifer L Smith, Adam Bisaga, et al.
Journal of Psychoactive Drugs|September 12, 2018
The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and AnxietyJermaine D Jones, Adam Bisaga, Verena E Metz, et al.
The American Journal on Addictions|August 16, 2011
A comparison of independent depression and substance-induced depression in cannabis-, cocaine-, and opioid-dependent treatment seekersElias Dakwar, Edward V Nunes, Adam Bisaga, et al.
Pharmacology, Biochemistry, and Behavior|October 12, 2017
Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potentialJermaine D Jones, Sandra D Comer, Verena E Metz, et al.
Addiction (Abingdon, England)|January 10, 2013
A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disordersFrances R Levin, John Mariani, Daniel J Brooks, et al.
Journal of Dual Diagnosis|May 12, 2009
Atomoxetine Treatment for Cocaine Abuse and Adult Attention-Deficit Hyperactivity Disorder (ADHD): A Preliminary Open TrialFrances R Levin, John J Mariani, Alex Secora, et al.
Drug and Alcohol Dependence|January 4, 2015
Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexoneMaria A Sullivan, Adam Bisaga, Andrew Glass, et al.
Drug and Alcohol Dependence|January 8, 2021
Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trialFrances R Levin, John J Mariani, Martina Pavlicova, et al.
Drug and Alcohol Dependence|July 1, 2011
A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependenceAdam Bisaga, Maria A Sullivan, Wendy Y Cheng, et al.
Pageof 10